The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age

英国药品和医疗保健产品管理局(MHRA)授予cel-sci的Multikine产品针对18岁以下青少年头颈癌治疗的特定豁免

Benzinga · 2024/09/04 21:03

CEL-SCI Corporation (NYSE:CVM) today reported it has received a decision letter from the United Kingdom's Healthcare Products Regulatory Agency (MHRA) granting Multikine (Leukocyte Interleukin, Injection)* a product specific waiver for the treatment of head and neck cancer in a pediatric population of people up to 18 years of age. As a result, CEL-SCI will not be required to evaluate Multikine in a pediatric population as part of license and marketing clearance review in the UK.

cel-sci 公司（纽交所:CVM）今天报告称，已收到英国医疗产品管制局（MHRA）的决定函，授予Multikine（白细胞白细胞介素，注射）*在18岁以下儿童人群中治疗头颈癌的产品特定豁免。因此，CEL-SCI将无需在英国对Multikine进行18岁以下儿童人群的评估，作为许可和营销许可审查的一部分。

译文内容由第三方软件翻译。

以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。

The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age

The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age

风险及免责提示

声明